Aebi S - Search Results

1

Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment.

Amstutz U, Farese S, Aebi S, Largiadèr CR. Amstutz U, et al. Among authors: aebi s. Pharmacogenomics. 2009 Jun;10(6):931-44. doi: 10.2217/pgs.09.28. Pharmacogenomics. 2009. PMID: 19530960

2

The impact of ABCC11 polymorphisms on the risk of early-onset fluoropyrimidine toxicity.

Hamzic S, Wenger N, Froehlich TK, Joerger M, Aebi S, Largiadèr CR, Amstutz U. Hamzic S, et al. Among authors: aebi s. Pharmacogenomics J. 2017 Jul;17(4):319-324. doi: 10.1038/tpj.2016.23. Epub 2016 Mar 22. Pharmacogenomics J. 2017. PMID: 27001120

3

Novel Genetic Variants in Carboxylesterase 1 Predict Severe Early-Onset Capecitabine-Related Toxicity.

Hamzic S, Kummer D, Milesi S, Mueller D, Joerger M, Aebi S, Amstutz U, Largiader CR. Hamzic S, et al. Among authors: aebi s. Clin Pharmacol Ther. 2017 Nov;102(5):796-804. doi: 10.1002/cpt.641. Epub 2017 May 30. Clin Pharmacol Ther. 2017. PMID: 28139840

4

Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy.

Amstutz U, Farese S, Aebi S, Largiadèr CR. Amstutz U, et al. Among authors: aebi s. J Exp Clin Cancer Res. 2008 Oct 20;27(1):54. doi: 10.1186/1756-9966-27-54. J Exp Clin Cancer Res. 2008. PMID: 18937829 Free PMC article.

5

Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity.

Froehlich TK, Amstutz U, Aebi S, Joerger M, Largiadèr CR. Froehlich TK, et al. Among authors: aebi s. Int J Cancer. 2015 Feb 1;136(3):730-9. doi: 10.1002/ijc.29025. Epub 2014 Jun 27. Int J Cancer. 2015. PMID: 24923815

6

Dihydropyrimidinase and β-ureidopropionase gene variation and severe fluoropyrimidine-related toxicity.

Kummer D, Froehlich TK, Joerger M, Aebi S, Sistonen J, Amstutz U, Largiadèr CR. Kummer D, et al. Among authors: aebi s. Pharmacogenomics. 2015;16(12):1367-77. doi: 10.2217/pgs.15.81. Epub 2015 Aug 5. Pharmacogenomics. 2015. PMID: 26244261

7

Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis.

Hamzic S, Kummer D, Froehlich TK, Joerger M, Aebi S, Palles C, Thomlinson I, Meulendijks D, Schellens JHM, García-González X, López-Fernández LA, Amstutz U, Largiadèr CR. Hamzic S, et al. Among authors: aebi s. Pharmacol Res. 2020 Feb;152:104594. doi: 10.1016/j.phrs.2019.104594. Epub 2019 Dec 12. Pharmacol Res. 2020. PMID: 31838077 Free article.

8

Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy.

Hamzic S, Aebi S, Joerger M, Montemurro M, Ansari M, Amstutz U, Largiadèr C. Hamzic S, et al. Among authors: aebi s. Swiss Med Wkly. 2020 Nov 24;150:w20375. doi: 10.4414/smw.2020.20375. eCollection 2020 Nov 16. Swiss Med Wkly. 2020. PMID: 33232506 Free article.

9

Clinical Implementation of DPYD Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland.

Begré UBM, Jörger M, Aebi S, Amstutz U, Largiadèr CR. Begré UBM, et al. Among authors: aebi s. Front Pharmacol. 2022 May 18;13:885259. doi: 10.3389/fphar.2022.885259. eCollection 2022. Front Pharmacol. 2022. PMID: 35662713 Free PMC article.

10

Infiltrating lobular carcinoma of the breast: systemic treatment.

Farese SA, Aebi S. Farese SA, et al. Among authors: aebi s. Breast Dis. 2008-2009;30:45-52. doi: 10.3233/BD-2009-0281. Breast Dis. 2008. PMID: 19850995 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

189 results

Search Page

Filters